JPRN-C000000429已完成1 期
oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalation - Oral CEF adjuvant chemotherapy
Outpatient Oncology Unit Kyoto University Hospital0 个研究点目标入组 26 人开始时间: 2006年6月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 69years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Infection, Fever = or > 38C Serious comorbidity Interstitial pneumonitis/fibrosis Peripheral neuropathy/edema Positive HBsAg Prior use of Anthracycline Decision by primary physician
研究者
相似试验
已完成
不适用
Fluorouracil / Epirubicin / Cyclophosphamide (FEC) followed by Docetaxel plus Cyclophosphamide (TC) as adjuvant chemotherapy for node positive breast cancerBreastCancerJPRN-UMIN000001077Kinki Multidisciplinary Breast Oncology Group35
进行中（未招募）
不适用
Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancerHER2neu-negative operable breast cancerEUCTR2009-009874-28-ATABCSG - Austrian Breast & Colorectal Cancer Study Group
已完成
不适用
Adjuvant cyclophosphamide, methotrexate and 5-Fluorouracil (CMF) versus 5-Fluorouracil, epirubicin and cyclosphosphamide (FEC) in node negative poor-risk primary breast cancerMalignant neoplasm of the breastCancerBreast cancerISRCTN81164554Pharmacia Ltd & Upjohn (UK)
进行中（未招募）
不适用
Sequential first line chemotherapy ECF (epirubicin + cisplatin + 5-fluoruracil) followed by DCF (docetaxel + cisplatin + 5-fluoruracil) in advanced/metastatic gastric cancer HER-2 negative: a phase II study - ECF-DCFpatients with advanced/metastatic gastric cancer not operable HER-2 negativeMedDRA version: 13.1Level: HLTClassification code 10017812Term: Gastric neoplasms malignantSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 13.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: HLGTClassification code 10017991Term: Gastrointestinal neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019756-42-ITAZIENDA OSPEDALIERA SENESE
已完成
2 期
Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancerBreast CancerJPRN-UMIN000009853Dokkyo Medical University23